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Abstract
Background: Enhanced signalling via the epidermal growth factor receptor (EGFR) is a hallmark of multiple human
carcinomas. However, in recent years data have accumulated that EGFR might also be hyperactivated in human
sarcomas. Aim of this study was to investigate the influence of EGFR inhibition on cell viability and its interaction
with chemotherapy response in osteosarcoma cell lines.
Methods: We have investigated a panel of human osteosarcoma cell lines regarding EGFR expression and
downstream signalling. To test its potential applicability as therapeutic target, inhibition of EGFR by gefitinib was
combined with osteosarcoma chemotherapeutics and cell viability, migration, and cell death assays were
performed.
Results: Osteosarcoma cells expressed distinctly differing levels of functional EGFR reaching in some cases high
amounts. Functionality of EGFR in osteosarcoma cells was proven by EGF-mediated activation of both MAPK and
PI3K/AKT pathway (determined by phosphorylation of ERK1/2, AKT, S6, and GSK3β). The EGFR-specific inhibitor
gefitinib blocked EGF-mediated downstream signal activation. At standard in vitro culture conditions, clinically
achievable gefitinib doses demonstrated only limited cytotoxic activity, however, significantly reduced long-term
colony formation and cell migration. In contrast, under serum-starvation conditions active gefitinib doses were
distinctly reduced while EGF promoted starvation survival. Importantly, gefitinib significantly supported the
anti-osteosarcoma activities of doxorubicin and methotrexate regarding cell survival and migratory potential.
Conclusion: Our data suggest that EGFR is not a major driver for osteosarcoma cell growth but contributes to
starvation- and chemotherapy-induced stress survival. Consequently, combination approaches including EGFR
inhibitors should be evaluated for treatment of high-grade osteosarcoma patients.
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Background
Osteosarcoma is the most common primary malignant
bone tumor with a peak incidence in childhood and ado-
lescence frequently occurring at sites of rapid bone
growth. The long-term survival of patients with osteo-
sarcoma has improved from 10 to 20 % to nearly 80 %
within the last 25 years, due to the use of neoadjuvant
chemotherapy [1]. However, this plateau has not chan-
ged for more than 15 years [2]. For patients with meta-
static disease, the outcomes are distinctly worse, with
less than 30 % survival at 5 years [3]. Furthermore some
patients do not respond to chemotherapy and others ex-
hibit features of multidrug resistance (MDR), probably
due to overexpression of P-glycoprotein (ABCB1) [4].
Consequently, there is still an urgent demand for new
and more effective therapeutic strategies.
The erbB family receptor tyrosine kinases play an im-
portant role in the control of cell cycle, proliferation, and
migration of normal and cancer cells. Expression of erbB
molecules, especially the epidermal growth factor receptor
(EGFR, erbB1), has been described in osteosarcomas [5].
This observation opens the possibility that EGFR might be
a feasible therapeutic target in osteosarcoma although ac-
tivating EGFR mutations are widely missing in this aggres-
sive primary bone tumor [5, 6]. EGFR-targeted therapies
(monoclonal antibodies or small molecule TK inhibitors)
have been already clinically approved for several tumors
including colorectal, non-small cell lung, head and neck,
as well as pancreatic cancer [7–9]. Gefitinib is a selective
EGFR tyrosine kinase inhibitor currently utilized for the
treatment of patients with non-small cell lung cancer har-
bouring activating EGFR mutations [10–12]. In the
present study, we investigated the impact of EGFR inhib-




Gefitinib (ZD1839, Iressa®, 4-quinazolinamine, N-(3-
chloro-4-flurophenyl)-7-methoxy-6-(3-(4-morpholinyl)
propoxy), a selective EGFR inhibitor, was kindly pro-
vided by AstraZeneca, and dissolved in sterile dimethyl
sulphoxide (DMSO). Solutions were freshly prepared be-
fore use. As standard chemotherapeutic agents in osteo-
sarcoma, doxorubicin, methotrexate (MTX) and
cisplatin were used (Sigma, Vienna, Austria). Stock solu-
tions were prepared for gefitinib at 10 mM in DMSO,
doxorubicin at 3.5 mM in saline, cisplatin at 4 mM in
dimethylformamide and MTX in a minimal amount of
1 M NaOH followed by saline to 200 mM.
Cell cultures
MG-63, HOS, Saos-2 and U-2 OS osteosarcoma cell
lines were obtained from the American Type Culture
Collection (Manassas, VA). Primary osteosarcoma cell
lines OS-10, OS-9, SARG and IOR-MOS were gener-
ously supplied by Dr. K. Scotlandi from the Instituti
Ortopedici Rizzoli (Bologna, Italy) [13, 14]. The HL-NG
cell line was established from a fibroblastic osteosarcoma
surgery specimen at the Institute of Cancer Research,
Vienna. Calu-3, an EGFR-overexpressing non-small cell
lung cancer cell line used as positive control, was ob-
tained from ATCC. Histological subtype of the original
tumors and culture media are indicated in Additional
file 1: Table S1. Cells were cultured in growth media
supplemented with 10 % fetal calf serum (FCS) at 37 °C
in a 5 % CO2 incubator. The cell lines were authenti-
cated in all cases by array comparative genomic
hybridization (Agilent, 44 k human whole genome DNA
arrays) as published [15] and/or short tandem repeat
(STR) fingerprinting before the start of this study.
Cell growth and viability assays
Cells were plated (2x104 cells/mL) in 100 μL per well in
96-well plates and allowed to attach for 24 h. Drugs
were added in another 100 μL growth medium and cells
exposed for 72 h. The proportion of viable cells was de-
termined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium assay (MTT) following the manufacturer’s
recommendations (EZ4U, Biomedica, Vienna, Austria).
Cytotoxicity was expressed as IC50 values calculated
from full dose–response curves. The interaction between
the activities of combined drugs is expressed by the
combination index (CI) as published by Heffeter et al.
[16] using CalcuSyn software (Biosoft, Ferguson, MO).
CI < 0.9, CI = 0.9–1.2 or CI >1.2 represent synergism,
additive effects and antagonism, respectively.
Apoptosis and cell cycle analyses
Induction of cell death was followed by staining of living
osteosarcoma cell cultures under different treatment and
serum conditions with Hoechst 33258 and propidium
iodide (PI) as published [17]. Hoechst dye enters living
cells and allows detection of chromatin condensation
due to either mitosis or apoptosis. In contrast, PI only
stains dead cells due to necrosis or apoptosis. Assays
were performed in 24-well plates in duplicate and 4 op-
tical fields per well were evaluated after 24 h by micro-
scopic counting of apoptotic cells. Cell cycle distribution
was analysed after 24 h exposure to gefitinib by PI stain-
ing of ethanol-fixed cells followed by FACS analysis as
published previously [17, 18].
Clonogenic assay
103 cells per well were seeded into six-well plates. Fol-
lowing 24 h recovery, cells were treated with MTX,
doxorubicin, cisplatin and gefitinib. At day 7 of expos-
ure, cells were washed twice with PBS, fixed with
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methanol at −20 °C and stained with crystal violet. The
number of colonies containing at least 100 single cells
was determined by counting microscopically using a
Leica DMIL (Leica, Solms, Germany).
Protein isolation and Western blotting
Total protein and membrane protein-enriched fractions
were extracted and processed for Western blotting as
described [19, 20] using the following primary anti-
bodies: pEGFR(Tyr1068), EGFR, phospho-S6 ribosomal
protein (Ser240/244), S6, phospho-p44/42 MAP kinase
ERK (Thr202/Tyr204), p44/42 MAP kinase ERK, pAKT
(Ser473), AKT, pGSK3β (Ser9), GSK3β, (all polyclonal
rabbit contained in the respective sampler kits from Cell
Signaling Technology, Beverly, MA), ß-actin monoclonal
mouse AC-15 (Sigma).
RNA isolation
Total RNA was isolated with Trizol reagent according to
standard protocols. RNA quantity and quality was deter-
mined by Nanodrop measurements (Nanodrop 1000,
Thermo Fisher Scientific, Wilmington, DE). Quantity
ranged between 150 and 400 ng/μl. All samples had a
260/280 ratio > 1.8.
Real-time PCR
1000 ng of total RNA were reverse transcribed into cDNA.
For real-time PCR 10 ng were used for each amplification
reaction (performed in triplicate). Real-time polymerase
chain reaction (PCR) was performed as described [21].
Expression levels of ABCB1 mRNA levels were deter-
mined using the Maxima SYBR Green/ROX qPCR Mas-
termix (Thermo Fisher Scientific) with β-actin serving as a
reference gene. ABCB1 primer sequence [22, 23]: ABCB1
sense: 5’-CCCATCATTGCAATAGCAGG-3’ and ABCB1
antisense: 5’-GTTCAAACTTCTGCTCCTGA-3’. β-actin
primer sequence: β-actin sense: 5’-GGATGCAGAAGGA-
GATCACTG-3’ and β-actin antisense: 5’-CGATCCA-
CACGGAGTACTTG-3’. For determination of EGFR
mRNA expression Taqman assays using Taqman Maxima
Probe/ROX qPCR Mastermix (Thermo Fisher Scientific)
were performed. Taqman probes for EGFR
(Hs01076078_m1) and GAPDH (Hs99999905_m1) were
purchased from (Applied Biosystems, Waltham, MA).
Quantification of ABCB1 and EGFR mRNA expression
was calculated by the comparative Ct method using
β-actin and GAPDH as reference genes, respectively.
Experiments were performed twice delivering comparable
results.
Migration assays
In wound healing assays, scratches were applied to con-
fluent cultures in six-well plates (tissue culture treated,
CytoOne® Starlab, Hamburg, Germany) using a pipette
tip. Medium was renewed and the indicated treatments
were added. Scratches were photographed after 0, 24
and 48 h and wound closure was calculated from the mi-
crographs with T-Scratch (Computational Science & En-
gineering Laboratory, ETH Zurich, Switzerland). After a
migration period of 24 h and 48 h, migrated cells on the
bottom of the filter (cell culture insert for 24-well plates,
8.0 μm pore size, Falcon™ ThermoFisher Scientific) were
counted (4 optical fields per well). Additionally, the bot-
tom wells were further cultivated for 7 more days, fixed
with methanol, stained with crystal violet and cell clones
counted microscopically.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.0 software. All data are expressed as mean ± S.D. Stat-
istical significance of differences was analysed by using
unpaired Student s t-test and one-or two-way ANOVA
as appropriate followed by Bonferroni post-tests. A p-
value < 0.05 was considered statistically significant.
Throughout the study the following classification is
used: *, p < 0.05; **, p < 0.01 ***, p < 0.001.
Results
Osteosarcoma cells express functional EGFR
EGFR was readily detectable in membrane protein-
enriched fractions from 7/9 cell models with HOS, IOR-
MOS and OS-10 cells showing high expression even
comparable to the EGFR-driven lung cancer cell line
Calu-3 (Fig. 1a). Expression in HL-NG and Saos-2 cells
was low and only visible after extended exposure time in
Western blot analysis (Additional file 2: Figure S1). The
respective EGFR mRNA was detectable by real-time
PCR in all osteosarcoma cell lines (Fig. 1a) and corre-
lated roughly with membrane-residing EGFR levels.
EGFR gene expression levels are opposed to histological
subtype and the well known predictive osteosarcoma
biomarker ABCB1 (P-glycoprotein) [4] in Additional file
1: Table S1. In order to determine functionality of EGFR
in osteosarcoma cells we selected four cell lines (HOS,
MG-63, OS-10, IOR-MOS) with high EGFR expression
for signal transduction analysis. Application of EGF for
15 min to serum-starved osteosarcoma cells led in most
cases to a distinct activation of EGFR phosphorylation
and of the respective downstream MAPK (ERK phos-
phorylation) and PI3K/AKT (AKT, S6, and GSK3β phos-
phorylation) signaling pathways (Fig. 1b, densitometric
quantification in Fig. 1c). EGFR activation restored sig-
nal transduction in the majority of the tested cell models
to the level of unstarved cells (10 % FCS) or even dis-
tinctly higher. Application of gefitinib significantly
blocked EGF-mediated activation of the PI3K/AKT and
ERK pathways even below the serum-starved control
(IOR-MOS cells are shown representatively as a highly
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EGF-responsive cell model in Fig. 2a, b). In contrast,
pathway activation by FCS was comparably insensitive
against EGFR inhibition. Interestingly, residual phos-
phorylation of AKT and S6 under serum-starved condi-
tions was further reduced by gefitinib.
Osteosarcoma cells are comparably insensitive to EGFR
blockade at standard culture conditions but sensitive at
serum starvation
At standard culture conditions with 10 % FCS, treat-
ment with increasing concentrations of gefitinib for
72 h caused a dose-dependent decrease in the
number of viable cells in all tested osteosarcoma cell
lines with significantly differing sensitivities (Table 1).
However, all IC50 values were generally above 10 μM
thus distinctly exceeding clinical achievable doses
[24]. In contrast, IC50 values for gefitinib dramatically
dropped at serum-reduced starvation conditions (0.1
and 1 % FCS) in all osteosarcoma cell lines except U-
2 OS. Accordingly, application of EGF in an appropri-
ate dose range (which differed between cell lines) pro-
tected osteosarcoma cells against serum starvation
independent of the endogenous EGFR expression level
(examples for cell lines with high endogenous EGFR
A C
B
Fig. 1 Expression and functionality of EGFR in osteosarcoma cell lines. a Western blot analysis of EGFR in 9 membrane protein-enriched fractions
prepared from human osteosarcoma cell lines is opposed to an extract from Calu 3, a gefitinib-sensitive NSCLC cell line, used as a positive control.
β-actin is shown as loading control. EGFR mRNA expression levels are indicated relatively to Calu 3 set as 1. b Four representative osteosarcoma
cell lines with enhanced EGFR expression were either cultured under FCS at 10 % (10 % FCS), serum-starved for 24 h (0 % FCS) or stimulated with
EGF (50 ng/ml for 15 min) following serum starvation for 24 h (EGF). The impact on EGFR phosphorylation and downstream activation of MAPK
(ERK) and PI3K (AKT, S6, GSK3β) signaling pathways was determined by Western blot analysis. c Bar charts depict densitometric quantification of
the Western blots (ImageJ Software) from (b) and data are given as phosphorylation of the indicated proteins relative to serum-starved conditions
(0 % FCS)
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Fig. 2 (See legend on next page.)
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expression in Fig. 2c and Additional file 3: Figure
S2A and with comparable low expression levels in
Additional file 3: Figure S2B). A comparable growth
stimulating effect of EGF was not detectable at stand-
ard culture conditions (data not shown). Gefitinib at-
tenuated or blocked this protective effect and
suppressed viability in some cases even below the
serum-starved control. Solely viability of the highly
EGFR positive cell line OS-10 could not be enhanced
by application of exogenous EGF despite high gefitinib
responsiveness under serum-starved conditions (data not
shown, compare Table 1). The anti-osteosarcoma effect of
gefitinib was based on enhanced apoptosis induction at
lower serum concentrations (three osteosarcoma cell lines
with different EGFR expression levels are shown in
Additional file 4: Figure S3). Additionally, surviving cells
accumulated either in G0/G1 or S cell cycle phase depend-
ing on the cell line tested (Additional file 5: Figure S4).
Impact of EGFR blockade on osteosarcoma cell migration
Next, the effect of EGFR blockade by gefitinib on osteosar-
coma cell migration was determined using trans-well as-
says (Fig. 3). The indicated osteosarcoma cells exhibited
significantly reduced migratory potential following EGFR
inhibition leading to elongated time frames of transmem-
brane passage.
Gefitinib sensitizes osteosarcoma cells against
chemotherapy
The impact of a combined application of the EGFR in-
hibitor gefitinib with standard chemotherapy used in
osteosarcoma cells (e.g. doxorubicin, MTX, cisplatin)
was tested for short- and long-term exposure by MTT
(72 h) and clonogenic (7 days) assays, respectively. In
Table 1 Anticancer activity of gefitinib as a single agent against
9 osteosarcoma cell lines
Gefitinib (IC50; μM)a
FCSb
Cell line 0.1 % 1 % 10 %
HL-NG 6.9 6.1 9.2
MG-63 5.1 15.3 16.3
HOS 12.1 18.2 19.9
Saos-2 13.8 21.5 27.1
OS-10 6.0 10.1 32.8
OS-9 7.3 8.5 29.5
SARG 3.6 4.1 31.2
IOR-MOS 2.8 10.4 31.5
U-2 OS 28.1 35.9 36.0
aGefitinib concentrations causing a reduction of cell viability by 50 % as
compared to the untreated controls
bAmount of fetal calf serum (FCS) added to the respective growth media
Fig. 3 EGF/EGFR-mediated signals contribute to the migratory
potential of osteosarcoma cells. Transwell migration assays (two
experiments in duplicate) were performed for 24 h and 48 h in
growth medium with 1 % FCS without and with addition of
gefitinib as indicated. Migrated cells at the lower side of the
membrane were counted microscopically in 4 optical fields/
membrane in duplicate and normalized to the untreated control.
One-way ANOVA with Bonferroni’s post hoc test; * p < 0.05; **
p < 0.01; *** p < 0.001
(See figure on previous page.)
Fig. 2 Impact of EGF and EGFR inhibition by gefitinib on signaling pathway activation and starvation survival of osteosarcoma cells. a The impact
of gefitinib (10 μM, 30 min) as indicated on phosphorylation of EGFR, ERK, S6, AKT and GSK3β in IOR-MOS cells either cultured under 10 % FCS
(unstarved), serum-starved for 24 h (0 % FCS) or stimulated after serum starvation with EGF (50 ng/ml, 15 min; EGF) or 10 % FCS (10 % FCS) was de-
termined by Western blot analysis. b Densitometric quantification of Western blots (ImageJ Software) from three experiments (one representative
shown under a) for the indicated signal proteins. Data are given relative to the phosphorylation levels at serum-starved conditions set as 1. c Via-
bility of IOR-MOS cells was determined by MTT assays after 72 h serum starvation (1 % or 0.1 % FCS as indicated) under increasing EGF concentra-
tions without or with gefitinib (5 μM). Significance of the gefitinib impact: two-way ANOVA with Bonferroni’s post hoc test; * p < 0.05; ** p < 0.01
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the MTT assay gefitinib moderately but significantly
synergized with doxorubicin in most (U-2 OS, MG-63,
HOS, Saos-2, OS-9 and OS-10) and MTX in several
(Saos-2, OS-9 and OS-10) osteosarcoma cell lines
(growth curves and combination indices representatively
shown for OS-10 cells in Fig. 4). In contrast, EGFR in-
hibition generally antagonized the effect of cisplatin
(Fig. 4). The sensitizing effect against doxorubicin and
MTX was markedly stronger in the long-term exposure
experiments and observable already at 1 μM gefitinib in
all tested cell lines (Fig. 5a and b). With regard to the
migratory potential, combined application of gefitinib
and standard chemotherapy further decreased migration
in wound healing analyses (HOS cells are shown repre-
sentatively in Fig. 6a). Clonogenic growth at the lower
chamber in trans-well migration assay (48 h migration)
was determined in several osteosarcoma cell lines
(Fig. 6b). Combined application of gefitinib and doxo-
rubicin resulted in synergistically decreased migration/
clonogenic potential compared to both doxorubicin and
gefitinib as single agents in three of four cell lines (HOS,
IOR-MOS and OS-10), whereas MG-63 cells remained
unaffected (data not shown).
Discussion
In accordance with previous studies on human osteosar-
coma cell lines and tissues [6, 25], we found frequent
and profound expression of EGFR in osteosarcoma cells
suggesting that it might be an attractive therapy target.
However, the actual functional contribution of EGFR to
osteosarcoma cell biology has remained widely unex-
plored and literature regarding its prognostic value is
A B
Fig. 4 Gefitinib sensitizes osteosarcoma cells against chemotherapy. a The effect of EGFR blockade by gefitinib at the indicated concentrations
on responsiveness to the standard osteosarcoma therapeutics doxorubicin, MTX and cisplatin was tested by MTT-based survival assays at 72 h
exposure time in triplicate. Representatively one out of three experiments for OS-10 cells is shown. b Combination Index (=CI) based on the data
under (a) were calculated as published. CI values < 0.9 indicates synergistic effects, CI = 0.9-1.2 additive and CI > 1.2 antagonistic effects
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Fig. 5 (See legend on next page.)
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Fig. 6 EGFR blockade synergizes with standard chemotherapy to inhibit the migratory potential of osteosarcoma cells. a For scratch assays, HOS
cells were treated with standard chemotherapy (MTX, doxorubicin) without and with 1 μM gefitinib and wound healing was followed at two
positions of the wound up to 48 h as indicated. Means and S.D. of two experiments are shown. b Transwell migration assays were performed
with HOS, IOR-MOS and OS-10 cells for 48 h at subtoxic concentrations of doxorubicin without and with 1 μM gefitinib. Clonogenic growth in
the lower chamber was analysed as under Fig. 3b. Selected wells containing crystal violet-stained osteosarcoma cell clones are opposed to quan-
tification of experiments performed in triplicate. One-way ANOVA with Bonferroni’s post hoc test (a) and Students t-test (b); * p < 0.05; ** p < 0.01;
*** p < 0.001
(See figure on previous page.)
Fig. 5 EGFR contributes to chemotherapy resistance of osteosarcoma cells. a Effects of combined long-term application of doxorubicin (Dox) and
gefitinib were tested by clonogenic survival assays. Representative wells with crystal violet-stained osteosarcoma cell clones (HOS, OS-10) are
opposed to the densitometric quantification from two experiments in triplicate. b Data for the combined application of MTX and gefitinib in the
long-term exposure were analysed as described under (a). Students t-test; * p < 0.05; ** p < 0.01; *** p < 0.001
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contradictory. Some authors did not find a relation be-
tween EGFR expression and prognosis or treatment out-
come [6, 26]. In contrast, high EGFR expression was
associated with significantly shorter survival times and
disease free intervals in canine osteosarcomas [27]. Fur-
thermore, Wen et al. found increased EGFR levels in
metastases and local recurrences when compared with
primary tumors [5]. Surprisingly, better prognosis was
reported for patients with higher EGFR expression by
Kersting et al. [28] A shorter allele length of a CA re-
peating sequence in the intron I of the EGFR gene
tended to be associated with increased EGFR expression.
However there was no correlation between allele length
and neoadjuvant chemotherapy response or long-term
clinical outcome [29]. Additionally, targeting of EGFR by
cetuximab was suggested to induce osteosarcoma
growth inhibition via antibody-dependent tumor cell
phagocytosis by a M2-like macrophage subpopulation
[30].
In our study we could demonstrate functionality of the
EGFR in osteosarcoma cell lines leading to EGF-
mediated activation of the MAPK and PI3K/AKT path-
ways. Moreover, blockade of EGFR by gefitinib inhibited
osteosarcoma cell proliferation at standard culture con-
ditions only at comparably high concentrations not likely
to be reached in vivo. This suggests that EGFR is not a
central driver of osteosarcoma cell proliferation under in
vitro cell culture conditions. Accordingly, gefitinib up to
20 μM did not reduce viability of several osteosarcoma
cell lines in a previous study [6]. However, under re-
duced serum concentrations, mimicking the starvation
situation inside tumor nodules in vivo, the IC50 values
for gefitinib distinctly dropped. Also in other cellular
stress conditions - including very sparse seeding in clo-
nogenic assays and chemotherapy-induced cytotoxicity -
EGFR-mediated signals supported osteosarcoma cell sur-
vival. At serum-reduced conditions, EGFR inhibition by
gefitinib induced marked apoptotic osteosarcoma cell
death. Additionally, gefitinib led to accumulation of cells
in either G0/G1 or S phase of the cell cycle. Comparable
observations have been published as a consequence of
imatinib mesylate exposure of osteosarcoma cells. Inter-
estingly, the authors suggested EGFR as one important
target inhibited by this clinically approved kinase inhibi-
tor [31]. Moreover, osteosarcoma cell migration was sig-
nificantly reduced by EGFR blockade and this effect was
synergistically enhanced in combination with chemo-
therapy. These data are in accordance with a previous
study demonstrating that selective in vitro inhibition of
EGFR induced decreased motility, colony formation and
invasiveness of osteosarcoma cells [32]. The non-
selective pan-erbB inhibitor CI-1033 achieved IC50
values at concentrations of approximately 1 μM after
4 days of drug exposure [33]. Pahl et al. showed
cytotoxic effect of the anti-EGFR monoclonal antibody
cetuximab induced by natural killer cell activation and
following lysis of osteosarcoma cells [34]. In both latter
studies cytotoxic activity was not correlated with the
level of EGFR expression. This is similar to our observa-
tions that neither the growth-inhibitory nor cell death-
inducing effects of gefitinib were depending on the level
of endogenous EGFR expression. Additionally, EGFR
levels did not correlate with the histology of the original
tumor. Interestingly exogenous EGF upregulated viabil-
ity of osteosarcoma cells in the majority but not all cell
lines tested. Thus, the highly EGFR-positive and
gefitinib-sensitive OS-10 cell line was surprisingly not
responsive to recombinant EGF under serum starvation.
This suggests that EGFR might be stimulated even under
serum-starved conditions by endogenous ligands in this
cell model. Correspondingly, gefitinib reduced residual
PI3K/AKT pathway activity determined as phosphoryl-
ation of AKT, S6 and GSK3β under serum-starved con-
ditions. This strongly suggests that autocrine
stabilisation of the PI3K/AKT pathway via EGFR sup-
ports starvation resistance of osteosarcoma cells as also
observed in glioblastoma cells [20]. Accordingly, activa-
tion of PI3K/AKT pathway and osteosarcoma cell migra-
tion was recently demonstrated by endogenous
expression of transforming growth factor α via binding
to EGFR [35].
In many clinical treatment schemes, combination ap-
proaches of oncogenic kinase inhibitors and cytotoxic
drugs turned out to be highly successful [36–38]. Thus,
we investigated combination of EGFR inhibition by gefi-
tinib with osteosarcoma standard chemotherapeutics.
We detected distinct synergism for combination with
doxorubicin and MTX in osteosarcoma cells. ABCB1 ef-
flux pump expression has been suggested as a major
regulator of osteosarcoma chemotherapy response [4].
As gefitinib is known to block ABCB1 efflux function
[39], the observed synergism with the ABCB1 substrate
doxorubicin might be based rather on enhanced drug ac-
cumulation as blockade of an EGFR-mediated survival
function. However, ABCB1 gene expression detected by
real-time PCR was comparably low in all osteosarcoma
cell lines making this assumption unlikely. Accordingly,
synergism was also found for the none ABCB1 substrate
MTX [40], while the combination with cisplatin, also
not transported by ABCB1, was widely antagonistic. Sev-
eral previous preclinical studies on other tumor entities
have shown additive and super-additive but also antag-
onistic interactions for EGFR inhibitors and chemother-
apy [41, 42]. Repeatedly, studies on EGFR targeting
combined with cytotoxic drugs have been confirmed
clinically, the most convincing being the therapeutic suc-
cess achieved by the cetuximab-irinotecan combination
in colorectal cancer [43]. Combination of gefitinib with
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doxorubicin in soft tissue sarcomas showed synergistic
impacts on cell proliferation and apoptosis induction
compared to single agents. Furthermore, in animal
models for soft tissue sarcoma combined low-dose doxo-
rubicin and gefitinib were markedly synergistic [44].
Two clinical phase I studies with advanced solid tu-
mors revealed partial responses for a combination ther-
apy of the EGFR inhibitors gefitinib and erlotinib with
both cediranib (VEGFR inhibitor) and temozolomide
[45, 46]. Only 3 patients with osteosarcoma were in-
cluded in these studies. One of them developed a partial
response, which is encouraging for further studies on
drug combination including EGFR tyrosine kinase inhib-
itors in osteosarcoma.
Conclusions
EGFR-mediated survival signals protect human osteosar-
coma cells against cellular stress conditions including
several antineoplastic drugs. Consequently, combination
approaches of EGFR inhibitors in addition to chemo-
therapy should be evaluated for treatment of high-grade
osteosarcoma patients.
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